

MRP1/ABCC1 (D7O8N) Rabbit mAb



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Information Western Blotting Immunoprecipitation Immunoprecipitation Immunoprecipitation Immunoprecipitation Immunoprecipitation Immunoprecipitation Immunoprecipitation Immunoprecipitation Interview Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less 0.02% sodium azide. Store at ~20°C. Do not aliquot the antibody. MRP1/ABCC1 (D708N) Rabbit mAb recognizes endogenous levels of total MRP1 protein. Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding valtary of human ABCC1 protein. Background Multidrug resistance-associated protein 1 (MRP1/ABCC1) is a member of the MRP subfamily of binding cassette (ABC) transporters (1). MRP1/ABCC1 protein functions as an organic anion tratina a broad range of substrates, including antineoplastic or therapeutic agents and the glute (GSH) conjugates of these compounds. MRP1/ABCC1 also transports physiological substrates so folates, GSH and GSH disulfide (GSSG) conjugates of steroids, leukotrienes, and prostaglandins Although MRP1/ABCC1 is generally expressed in normal tissue, upregulation of MRP1/ABCC1 found in a variety of solid tumors, including small cell lung cancer, breast cancer, and prostate (1,4,5). Research studies show that overexpression of MRP1/ABCC1 and prostate and small cell lung cancer, breast cancer and small cell lung cancer, breast cancer and prostate and small cell lung cancer, are level of MRP1/ABCC1 is predictive of the response and toxicity chemotherapeutic agents from cancer cells and confers drug resistance in those patients. Research is also show that elevated expression of MRP1/ABCC1 is predictive of the response and toxicity chemotherapeutic agents in those patients (6-10). Background References I. Cole, S.P. et al. (1992) Science 258, 1650-4. 2. Pajic, M. et al. (2005) Fance 1000 FEBS Lett 580, 1103-11. 4. Atalay, C. et al. (2005) Fance 1000 FEBS Lett 580, 1103-11. 5. Sánchez, C. et al. (2006) Fance 1000 FEBS Lett 580, 1103-11. 5. Sánchez, C. et al. (2009) Fance 1000	Applications: W, IP, IF-IC	Reactivity: H	Sensitivity: Endogenous	MW (kDa): 170-220	Source/Isotype: Rabbit IgG	UniProt ID: #P33527	Entrez-Gene Id 4363
O.02% sodium azide. Store at ~20°C. Do not aliquot the antibody. Specificity/Sensitivity MRP1/ABCC1 (D708N) Rabbit mAb recognizes endogenous levels of total MRP1 protein. Monoclonal antibody is produced by immunizing animals with a synthetic peptide correspondiresidues surrounding Val273 of human ABCC1 protein. Multidrug resistance-associated protein 1 (MRP1/ABCC1) is a member of the MRP subfamily of binding cassette (ABC) transporters (1), MRP1/ABCC1 protein functions as an organic anion trail It has a broad range of substrates, including antineoplastic or therapeutic agents and the glut (GSH) conjugates of these compounds, MRP1/ABCC1 also transports physiological substrates s folates, GSH and GSH disulfide (GSSG) conjugates of steroids, leukotrienes, and prostaglandins Although MRP1/ABCC1 is generally expressed in normal tissue, upregulation of MRP1/ABCC1 found in a variety of solid tumors, including small cell lung cancer, breast cancer, and prostate (1,4,5). Research studies show that overexpression of MRP1/ABCC1 is found in a variety of solid tumors, including small cell lung cancer, breast cancer, and prostate and small cell lung cancer cells and confers drug resistance in those patients. Research s also show that elevated expression of MRP1/ABCC1 is a negative prognostic marker for breast and small cell lung cancer, as the level of MRP1/ABCC1 is predictive of the response and toxicity chemotherapeutic agents in those patients (6-10). Background References 1. Cole, S.P. et al. (1902) Science 258, 1650-4. 2. Pajic, M. et al. (2005) Cancer Lett 228, 241-6. 3. Deeley, R.G. and Cole, S.P. (2006) FEBS Lett 580, 1103-11. 4. Atalay, C. et al. (2006) Tumour Biol 27, 309-18. 5. Sánchez, C. et al. (2010) Tumour Biol 27, 309-18. 5. Sánchez, C. et al. (2010) Tumour Biol 27, 309-18. 5. Sánchez, C. et al. (2010) Tumour Biol 27, 309-18. 5. Sánchez, C. et al. (2002) Lung 180, 173-9. 8. Kuo, T.H. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2002) Lung 180, 173-9. 10. Vulsteke, C. et al. (2013) Ann			Western Blotting Immunoprecipitation		istry)		1:100
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding residues surrounding Val273 of human ABCC1 protein. Multidrug resistance-associated protein 1 (MRP1/ABCC1) is a member of the MRP subfamily of binding cassette (ABC) transporters (1). MRP1/ABCC1 protein functions as an organic anion tra It has a broad range of substrates, including antineoplastic or therapeutic agents and the glut (GSH) conjugates of these compounds. MRP1/ABCC1 also transports physiological substrates s folates, GSH and GSH disulfide (GSSG) conjugates of steroids, leukotrienes, and prostate. Although MRP1/ABCC1 is generally expressed in normal tissue, upregulation of MRP1/ABCC1 if found in a variety of solid tumors, including small cell lung cancer, breast cancer, and prostate. (14.65). Research studies show that overexpression of MRP1/ABCC1 is intended in the proposed and small cell lung cancer, and solid televated expression of MRP1/ABCC1 is predictive or therese and small cell lung cancer, as the level of MRP1/ABCC1 is predictive or the response and toxicing chemotherapeutic agents in those patients (6-10). Background References 1. Cole, S.P. et al. (1992) Science 258, 1650-4. 2. Pajic, M. et al. (2005) Cancer Lett 228, 241-6. 3. Deeley, R.G. and Cole, S.P. (2006) FEBS Lett 580, 1103-11. 4. Atalay, C. et al. (2006) FEBS Lett 580, 1103-11. 4. Atalay, C. et al. (2006) Tumour Biol 27, 309-18. 5. Sánchez, C. et al. (2006) Tumour Biol 27, 309-18. 5. Sánchez, C. et al. (2006) Tumour Biol 27, 309-18. 5. Sánchez, C. et al. (2006) Tumour Biol 27, 309-18. 5. Sánchez, C. et al. (2006) Tumour Biol 27, 309-18. 6. Nooter, K. et al. (1997) Br.J Cancer 76, 486-93. 7. Hsia, T.C. et al. (2006) Tumour Biol 27, 309-18. 9. Sánchez, C. et al. (2007) Prostate 69, 1448-59. 10. Vulsteke, C. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2006) Tumour Biol 27, 309-18. 10. Vulsteke, C. et al. (2007) Prostate 69, 1448-59. 10. Vulsteke, C. et al. (2008) Tumour Biol 27, 309-18. 10. Vulsteke, C. et al. (2008) Tu	Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.				
Background Multidrug resistance-associated protein 1 (MRP1/ABCC1) is a member of the MRP subfamily of binding cassette (ABC) transporters (1). MRP1/ABCC1 protein functions as an organic anion tra It has a broad range of substrates, including antineoplastic or therapeutic agents and the glute (GSH) conjugates of these compounds. MRP1/ABCC1 also transports physiological substrates s folates, GSH and GSH disulfide (GSSG) conjugates of steroids, leukotrienes, and prostaglandins Although MRP1/ABCC1 is generally expressed in normal tissue, upregulation of MRP1/ABCC1 if found in a variety of solid tumors, including small cell lung cancer, breast cancer, and prostate (1,4,5). Research studies show that overexpression of MRP1/ABCC1 facilitates the elimination on therapeutic agents from cancer cells and confers drug restance in those patients. Research s also show that elevated expression of MRP1/ABCC1 is predictive of the response and toxicity chemotherapeutic agents in those patients (6-10). Background References 1. Cole, S.P. et al. (1992) Science 258, 1650-4. 2. Pajic, M. et al. (2005) Cancer Lett 228, 241-6. 3. Deeley, R.G. and Cole, S.P. (2006) FBBS Lett S80, 1103-11. 4. Atalay, C. et al. (2003) Tumour Biol 27, 309-18. 5. Sánchez, C. et al. (2011) Prostate 71, 1810-7. 6. Nooter, K. et al. (1997) Brostate 71, 1810-7. 6. Nooter, K. et al. (1997) Brostate 71, 1810-7. 6. Nooter, K. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2003) Nucl Med Biol 30, 627-32. 9	Specificity/Sensitivity		MRP1/ABCC1 (D7O8N) Rabbit mAb recognizes endogenous levels of total MRP1 protein.				
binding cassette (ABC) transporters (1). MRP1/ABCC1 protein functions as an organic anion tra It has a broad range of substrates, including antineoplastic or therapeutic agents and the glute (GSH) conjugates of these compounds. MRP1/ABCC1 also transports physiological substrates of folates, GSH and GSH disulfide (GSSG) conjugates of steroids, leukotrienes, and prostately found in a variety of solid tumors, including small cell lung cancer, breast cancer, and prostate- (1,4,5). Research studies show that overexpression of MRP1/ABCC1 facilitates the elimination of the through mreast cancer, and prostate- (1,4,5). Research studies show that overexpression of MRP1/ABCC1 facilitates the elimination of the through mreast and small cell lung cancer, as the level of MRP1/ABCC1 is a negative prognostic marker for breast and small cell lung cancer, as the level of MRP1/ABCC1 is a predictive of the response and toxicity chemotherapeutic agents in those patients (6-10). Background References 1. Cole, S.P. et al. (1992) Science 258, 1650-4. 2. Pajic, M. et al. (2005) Cancer Lett 228, 241-6. 3. Deeley, R.G. and Cole, S.P. (2006) FEBS Lett 580, 1103-11. 4. Atalay, C. et al. (2006) Tumour Biol 27, 309-18. 5. Sánchez, C. et al. (2011) Prostate 71, 1810-7. 6. Nooter, K. et al. (1997) Br J Cancer 76, 486-93. 7. Hsia, T.C. et al. (2011) Prostate 71, 1810-7. 8. Kuo, T.H. et al. (2002) Lung 180, 173-9. 8. Kuo, T.H. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2013) Ann Oncol 24, 1513-25. Species Reactivity Species reactivity is determined by testing in at least one approved application (e.g., western b TMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v n dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight. Applications Key W: Western Blotting IP: Immunoprecipitation IF-IC: Immunofluorescence (Immunocytochemis	Source / Purification		Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val273 of human ABCC1 protein.				
found in a variety of solid tumors, including small cell lung cancer, breast cancer, and prostate (1,4,5). Research studies show that overexpression of MRP1/ABCC1 facilitates the elimination on therapeutic agents from cancer cells and confers drug resistance in those patients. Research s also show that elevated expression of MRP1/ABCC1 is a negative prognostic marker for breast and small cell lung cancer, as the level of MRP1/ABCC1 is predictive of the response and toxicity chemotherapeutic agents in those patients (6-10). Background References 1. Cole, S.P. et al. (1992) Science 258, 1650-4. 2. Pajic, M. et al. (2005) Cancer Lett 228, 241-6. 3. Deeley, R.G. and Cole, S.P. (2006) FEBS Lett 580, 1103-11. 4. Atalay, C. et al. (2001) Tumour Biol 27, 309-18. 5. Sánchez, C. et al. (2011) Prostate 71, 1810-7. 6. Nooter, K. et al. (1997) Br J Cancer 76, 486-93. 7. Hsia, T.C. et al. (2002) Lung 180, 173-9. 8. Kuo, T.H. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2013) Ann Oncol 24, 1513-25. Species Reactivity Species reactivity is determined by testing in at least one approved application (e.g., western b dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight. Applications Key W: Western Blotting IP: Immunoprecipitation IF-IC: Immunofluorescence (Immunocytochemis Cross-Reactivity Key H: Human	Background		Multidrug resistance-associated protein 1 (MRP1/ABCC1) is a member of the MRP subfamily of ATP-binding cassette (ABC) transporters (1). MRP1/ABCC1 protein functions as an organic anion transporter. It has a broad range of substrates, including antineoplastic or therapeutic agents and the glutathione (GSH) conjugates of these compounds. MRP1/ABCC1 also transports physiological substrates such as folates, GSH and GSH disulfide (GSSG) conjugates of steroids, leukotrienes, and prostaglandins (2,3).				
2. Pajic, M. et al. (2005) Cancer Lett 228, 241-6. 3. Deeley, R.G. and Cole, S.P. (2006) FEBS Lett 580, 1103-11. 4. Atalay, C. et al. (2006) Tumour Biol 27, 309-18. 5. Sánchez, C. et al. (2011) Prostate 71, 1810-7. 6. Nooter, K. et al. (1997) Br J Cancer 76, 486-93. 7. Hsia, T.C. et al. (2002) Lung 180, 173-9. 8. Kuo, T.H. et al. (2003) Nucl Med Biol 30, 627-32. 9. Sánchez, C. et al. (2009) Prostate 69, 1448-59. 10. Vulsteke, C. et al. (2013) Ann Oncol 24, 1513-25. Species Reactivity Species reactivity is determined by testing in at least one approved application (e.g., western b my milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight. Applications Key W: Western Blotting IP: Immunoprecipitation IF-IC: Immunofluorescence (Immunocytochemis Immunospherication III) Human			found in a variety of s (1,4,5). Research studi therapeutic agents fro also show that elevate and small cell lung ca	olid tumors, includi ies show that overe om cancer cells and ed expression of MF ncer, as the level of	ng small cell lung cance xpression of MRP1/ABC0 confers drug resistance RP1/ABCC1 is a negative MRP1/ABCC1 is predictiv	r, breast cancer, and C1 facilitates the eli e in those patients. prognostic marker	d prostate cancer mination of Research studies for breast cancer
Western Blot Buffer IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v n dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight. Applications Key W: Western Blotting IP: Immunoprecipitation IF-IC: Immunofluorescence (Immunocytochemis H: Human	Background References		 Pajic, M. et al. (2005) Cancer Lett 228, 241-6. Deeley, R.G. and Cole, S.P. (2006) FEBS Lett 580, 1103-11. Atalay, C. et al. (2006) Tumour Biol 27, 309-18. Sánchez, C. et al. (2011) Prostate 71, 1810-7. Nooter, K. et al. (1997) Br J Cancer 76, 486-93. Hsia, T.C. et al. (2002) Lung 180, 173-9. Kuo, T.H. et al. (2003) Nucl Med Biol 30, 627-32. Sánchez, C. et al. (2009) Prostate 69, 1448-59. 				
dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight. Applications Key W: Western Blotting IP: Immunoprecipitation IF-IC: Immunofluorescence (Immunocytochemis Cross-Reactivity Key H: Human	Species Reactiv	vity	Species reactivity is de	etermined by testin	g in at least one approve	ed application (e.g.,	western blot).
Cross-Reactivity Key H: Human	Western Blot Buffer		IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				
	Applications Key		W: Western Blotting IP: Immunoprecipitation IF-IC: Immunofluorescence (Immunocytochemistry)				
Trademarks and Patents Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.	Cross-Reactivity Key		H: Human				
	Trademarks and Patents		Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.				

XP is a registered trademark of Cell Signaling Technology, Inc.

more information.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party. whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.